Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibit... (the treatment of HIV. We haveevaluated o...)

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

Date:5/22/2008

the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
2. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 RxAlly , ... nationwide, announces today the publication of a white ... Health Care System. The white paper highlights an ... and seeks public engagement to avert strains on ... Care refers to a range of individually-tailored, pharmacist-provided ...

(Date:5/20/2013)... 2013 Volcano Corporation (NASDAQ: VOLC ) ... tools designed to enhance the diagnosis and treatment of ... highlight its efforts to expand research and innovation surrounding ... and iFR ® (Instant Wave-Free Ratio™) 1 ... at EuroPCR 2013 in Paris . ...

(Date:5/20/2013)... Ill. , May 20, 2013 Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... announced today that its Board of Directors declared, at ... cash dividend of $0.55 per share for the third ... on July 3, 2013, to shareholders of record on ...

Breaking Medicine Technology:RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2 RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4 Landauer, Inc. Declares Regular Cash Dividend 2

[0] RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care [0] Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 [0] Landauer, Inc. Declares Regular Cash Dividend

... CARY, N.C., Dec. 18 Cornerstone Therapeutics Inc. (Nasdaq CM: ... commercializing significant products primarily for the respiratory and related markets, ... 8:30 AM ET on Thursday, January 7, 2010, to discuss ... a press release outlining its financial guidance for 2010 prior ...

... , BOSTON, Dec. 18 Solos Endoscopy, Inc. (Pink Sheets: ... a significant design improvement to its MammoView(TM) ductoscope. In January ... stainless steel tip with a much stronger braided polyimide tip. ... made to our ductoscope. One of the major difficulties in ...

Cached Medicine Technology:Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010 2 Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010 3 Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope 2

Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010 Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope

(Date:5/21/2013)... 2013 Global Proving Ground (GPG), a ... largest online retailer of health and fitness supplements, are ... show, Warrior Island. “We cast the show by ... Twitter, with our unique social networking platform,” states show’s ... fighters on an island in the Pacific Ocean, where ...

(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...

(Date:5/21/2013)... Department of Defense Serum Repository (DoDSR), University of Cincinnati ... inflammatory bowel disease (IBD), which could help with earlier ... shown symptoms. , This finding, the first of its ... being presented via podium presentation by staff from Walter ... 2013, being held May 18-21 in Orlando, Fla. ...

(Date:5/21/2013)... New York (PRWEB) May 21, 2013 ... surgery robot lawsuit is nearing its conclusion in ... to Bloomberg.com, during closing statements yesterday, an attorney for ... alleging the company wanted to tie sales and services ... all the training to keep control of surgeons, to ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Go Classy ... today that they have redesigned their website featuring ... beach, pool, hot tubs, bars and dining. The website, ... resort including sales and guest reviews, will now have ... Jamaica itself, including pages on culinary local recipes, flora ...

Breaking Medicine News(10 mins):Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2 Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2 Health News:Biomarkers discovered for inflammatory bowel disease 2 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4 Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2

[0] Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island [0] Researchers find genetic risk factor for pulmonary fibrosis [0] Biomarkers discovered for inflammatory bowel disease [0] Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial [0] The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography

... Cancer Patients in HELIOS HospitalsBERLIN, March 10 ... gain access to the most modern radiotherapy treatments with ... is acquiring nine linear accelerators from Varian Medical Systems ... equipped with RapidArc(TM) technology for fast and comfortable treatments. ...

... awareness for children and adults with autismFAIRFIELD, Conn. ... Network ( www.AutismSupportNetwork.com ) and the Israeli Society ... announced an international alliance to help foster support ... autism spectrum disorder (ASD). The partnership provides for ...

... March 10 More physician leaders are embracing technological ... consider them clunky and unresponsive to their needs.Those are ... American College of Physician Executives (ACPE). The findings were ... Journal, ACPE,s journal of medical management.ACPE conducted the same ...

... HOUSTON, March 10 InPlace Medical Solutions ... pioneering telemedicine healthcare services for Scorpion Offshore ... ongoing pilot project makes Scorpion Offshore the ... with the full-service system of advanced healthcare, ...

... /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ... of the Company, will present at the Cowen and Company ... Place, on Wednesday, March 18, 2009 at 11:00 a.m. ET. ... presentation by visiting the "Events" section of the homepage of ...

... Quarter Adjusted FIFO EBITDA Increases 4.3% to $26.1 Million, ... Full Year Adjusted FIFO EBITDA Increases 15% to ... Year Net Cash Provided by Operating Activities Increases 130% ... $17.4 Million and Full Year Net Loss of $72.8 ...

Leading German Healthcare Group Selects Equipment and Software from Varian Medical Systems for Major Replacement Project Autism Support Network and the Israeli Society for Autistic Children Form International Alliance Survey Results: Health Care Technology Advances as Physician Frustration Grows Scorpion Offshore Inc. Pilot Project With InPlace Medical Solutions Sets New Standard for Offshore Medical Services Labopharm to present at Cowen 29th Annual Health Care Conference Duane Reade Holdings, Inc. Reports Fourth Quarter and Full Year 2008 Results

The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....

...

Medicine Products:

The Comprehensive Natural-Knee Cruciate Retaining System Lineage Acetabular Poly Liners - 32 mm ID Standard Liners - Hooded 10 degree liners The Protract Hip System - Hooded Liner